SOTIO Secures €280m of Funding to Expand and Advance Clinical Pipeline
Summary
• PPF Group provides funding to advance SOTIO through key clinical milestones • Proceeds shall be used to conduct two phase 2 studies with SOT101, including a checkpoint inhibitor combination trial • Three programs (SOT102, BOXR1030, and SOT201) to advance through phase 1 PRAGUE, Czech Republic and BASEL, Switzerland and CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- SOTIO Biotech, a clinical stage immuno-oncology companyowned by PPF Group,announced today that is has secured€280m of funding to significantly expand and advance its clinical pipeline, including its lead assetSOT101, an IL-15 superagonist, and three new clinical programs until the end of 2023. It’s based on the proprietary BOXR™ platform that aims to enhance the fitness of T cells in the hostile tumor microenvironment. Finally, SOTIO plans to initiate a phase 1 study with our first IL-15 based immunocytokine using a PD-1 inhibitor as the targeting arm by the end of 2022. “We are very excited and grateful for the continued strong support we’ve received from PPF Group today and since our inception,” said Radek Spisek, Ph.D., CEO of SOTIO. “This very significant funding will allow us to advance a broad pipeline of unique clinical stage programs to key value inflection points.” “Over the last several years SOTIO has created an attractive pipeline of programs based on multiple differentiated modalities,” said Ladislav Bartonicek, CEO and shareholder of PPF Group.